CymaBay Therapeutics, Inc. (CBAY) Reaches $12.51 After 7.00% Down Move; Phibro Animal Health – Class A Common (PAHC) Shorts Down By 1.7%

May 21, 2018 - By Michael Collier

Phibro Animal Health Corporation – Class A Common (NASDAQ:PAHC) had a decrease of 1.7% in short interest. PAHC’s SI was 190,800 shares in May as released by FINRA. Its down 1.7% from 194,100 shares previously. With 121,600 avg volume, 2 days are for Phibro Animal Health Corporation – Class A Common (NASDAQ:PAHC)’s short sellers to cover PAHC’s short positions. The SI to Phibro Animal Health Corporation – Class A Common’s float is 0.98%. The stock increased 0.11% or $0.05 during the last trading session, reaching $45.35. About 44,098 shares traded. Phibro Animal Health Corporation (NASDAQ:PAHC) has risen 41.44% since May 21, 2017 and is uptrending. It has outperformed by 29.89% the S&P500.

The stock of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) is a huge mover today! The stock decreased 2.87% or $0.37 during the last trading session, reaching $12.51. About 324,919 shares traded. CymaBay Therapeutics, Inc. (NASDAQ:CBAY) has risen 197.77% since May 21, 2017 and is uptrending. It has outperformed by 186.22% the S&P500.The move comes after 8 months negative chart setup for the $735.20M company. It was reported on May, 21 by Barchart.com. We have $11.63 PT which if reached, will make NASDAQ:CBAY worth $51.46M less.

CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. The company has market cap of $735.20 million. It engages in developing seladelpar , a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout. It currently has negative earnings. The companyÂ’s product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes.

Analysts await CymaBay Therapeutics, Inc. (NASDAQ:CBAY) to report earnings on August, 9. They expect $-0.23 EPS, up 25.81% or $0.08 from last year’s $-0.31 per share. After $-0.32 actual EPS reported by CymaBay Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -28.13% EPS growth.

More recent CymaBay Therapeutics, Inc. (NASDAQ:CBAY) news were published by: Seekingalpha.com which released: “CymaBay Makes Progress With Seladelpar” on April 30, 2018. Also Nasdaq.com published the news titled: “CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic …” on May 08, 2018. Globenewswire.com‘s news article titled: “CymaBay to Report First Quarter 2018 Financial Results on Tuesday, May 8” with publication date: May 01, 2018 was also an interesting one.

Among 8 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cymabay Therapeutics Inc had 31 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating by Roth Capital given on Friday, July 1. Leerink Swann maintained CymaBay Therapeutics, Inc. (NASDAQ:CBAY) on Wednesday, March 28 with “Buy” rating. Oppenheimer maintained CymaBay Therapeutics, Inc. (NASDAQ:CBAY) on Wednesday, March 21 with “Buy” rating. The stock of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by Piper Jaffray on Tuesday, July 25. The firm earned “Buy” rating on Wednesday, January 31 by Piper Jaffray. Cantor Fitzgerald initiated CymaBay Therapeutics, Inc. (NASDAQ:CBAY) rating on Tuesday, September 19. Cantor Fitzgerald has “Buy” rating and $16.0 target. The stock of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) has “Buy” rating given on Wednesday, October 25 by Cantor Fitzgerald. As per Wednesday, January 10, the company rating was maintained by Oppenheimer. Leerink Swann maintained it with “Buy” rating and $16.0 target in Tuesday, November 28 report. Roth Capital initiated CymaBay Therapeutics, Inc. (NASDAQ:CBAY) rating on Thursday, January 25. Roth Capital has “Buy” rating and $27.0 target.

Investors sentiment decreased to 1.41 in Q4 2017. Its down 0.07, from 1.48 in 2017Q3. It turned negative, as 17 investors sold Phibro Animal Health Corporation shares while 42 reduced holdings. 25 funds opened positions while 58 raised stakes. 19.14 million shares or 1.25% less from 19.38 million shares in 2017Q3 were reported. State Of Wisconsin Investment Board accumulated 14,000 shares. Old National Financial Bank In owns 7,772 shares for 0.01% of their portfolio. Dimensional Fund L P owns 0.01% invested in Phibro Animal Health Corporation (NASDAQ:PAHC) for 478,044 shares. Moreover, Hbk Investments Limited Partnership has 0.01% invested in Phibro Animal Health Corporation (NASDAQ:PAHC). Cambridge Inv Advisors Incorporated, a Iowa-based fund reported 17,345 shares. Prudential has invested 0.01% in Phibro Animal Health Corporation (NASDAQ:PAHC). Swiss Retail Bank stated it has 31,900 shares or 0% of all its holdings. Ls Investment Advisors Ltd invested in 2,489 shares. Millennium Management Lc holds 419,998 shares. Mason Street Advsr Ltd Liability Co accumulated 5,093 shares. 3,000 are owned by First Manhattan Co. Victory Capital Mgmt has invested 0% of its portfolio in Phibro Animal Health Corporation (NASDAQ:PAHC). Assetmark Inc invested in 7 shares or 0% of the stock. Principal Financial Group Inc reported 0% of its portfolio in Phibro Animal Health Corporation (NASDAQ:PAHC). Geode Cap Management Limited Liability holds 189,537 shares.

Since February 9, 2018, it had 0 buys, and 13 selling transactions for $12.62 million activity. On Tuesday, February 27 the insider BENDHEIM JACK sold $1.38M. The insider BFI Co. – LLC sold $1.40M. Shares for $926,717 were sold by Bendheim Daniel M on Thursday, March 8. Warras Dean J also sold $356,200 worth of Phibro Animal Health Corporation (NASDAQ:PAHC) on Friday, February 9. 17,928 shares were sold by Miller Larry Lee, worth $630,886.

Among 9 analysts covering Philbro Animal Health (NASDAQ:PAHC), 3 have Buy rating, 4 Sell and 2 Hold. Therefore 33% are positive. Philbro Animal Health had 20 analyst reports since September 30, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, July 21 by Piper Jaffray. Credit Suisse maintained the shares of PAHC in report on Thursday, August 31 with “Outperform” rating. The firm earned “Buy” rating on Thursday, August 31 by Piper Jaffray. The company was initiated on Thursday, February 4 by Credit Suisse. Gabelli initiated Phibro Animal Health Corporation (NASDAQ:PAHC) on Wednesday, September 30 with “Buy” rating. On Friday, January 15 the stock rating was downgraded by Barclays Capital to “Underweight”. The firm has “Neutral” rating by Credit Suisse given on Tuesday, February 6. Gabelli downgraded the shares of PAHC in report on Thursday, November 10 to “Hold” rating. Piper Jaffray initiated the shares of PAHC in report on Thursday, December 15 with “Overweight” rating. Morgan Stanley maintained it with “Underweight” rating and $36 target in Wednesday, February 7 report.

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition firm primarily in the United States. The company has market cap of $1.83 billion. It operates through three divisions: Animal Health, Mineral Nutrition, and Performance Products. It has a 29.49 P/E ratio. The firm develops, makes, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture.

More recent Phibro Animal Health Corporation (NASDAQ:PAHC) news were published by: Globenewswire.com which released: “Phibro Animal Health Corporation Declares Quarterly Dividend” on May 07, 2018. Also Seekingalpha.com published the news titled: “Phibro Animal Health’s (PAHC) Management on Q3 2018 Results – Earnings Call Transcript” on May 11, 2018. Nasdaq.com‘s news article titled: “Research Report Identifies Albany International, JBG SMITH Properties, Preferred Apartment Communities, National …” with publication date: April 30, 2018 was also an interesting one.

Phibro Animal Health Corporation (NASDAQ:PAHC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>